The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) closed at $9.67 up 1.52% from its previous closing price of $9.52. In other words, the price has increased by $1.52 from its previous closing price. On the day, 0.6 million shares were traded. PHAT stock price reached its highest trading level at $9.9986 during the session, while it also had its lowest trading level at $9.39.
Ratios:
For a deeper understanding of Phathom Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.80 and its Current Ratio is at 7.83.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $24.
On January 05, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $23 to $26.
On August 09, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $28.H.C. Wainwright initiated its Buy rating on August 09, 2023, with a $28 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 08 ’24 when Henderson Molly sold 3,435 shares for $11.10 per share. The transaction valued at 38,128 led to the insider holds 95,263 shares of the business.
Curran Terrie sold 16,851 shares of PHAT for $153,513 on Mar 22 ’24. The President and Chief Executive now owns 410,784 shares after completing the transaction at $9.11 per share. On Jan 24 ’24, another insider, TAKEDA PHARMACEUTICAL CO LTD, who serves as the 10% Owner of the company, sold 3,703,703 shares for $8.10 each. As a result, the insider received 29,999,994 and left with 3,755,583 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 566035392 and an Enterprise Value of 722557120. For the stock, the TTM Price-to-Sale (P/S) ratio is 218.49. Its current Enterprise Value per Revenue stands at 278.549 whereas that against EBITDA is -3.498.
Stock Price History:
Over the past 52 weeks, PHAT has reached a high of $17.02, while it has fallen to a 52-week low of $6.07. The 50-Day Moving Average of the stock is -0.88%, while the 200-Day Moving Average is calculated to be -2.63%.
Shares Statistics:
For the past three months, PHAT has traded an average of 884.42K shares per day and 699560 over the past ten days. A total of 57.97M shares are outstanding, with a floating share count of 28.15M. Insiders hold about 51.90% of the company’s shares, while institutions hold 48.07% stake in the company. Shares short for PHAT as of 1714435200 were 11795035 with a Short Ratio of 13.34, compared to 1711584000 on 10647009. Therefore, it implies a Short% of Shares Outstanding of 11795035 and a Short% of Float of 41.4.
